HC Wainwright Has Pessimistic View of Kamada FY2025 Earnings

Kamada Ltd. (NASDAQ:KMDA) – Stock analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Kamada in a research note issued on Thursday, March 6th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn $0.28 per share for the year, down from their previous forecast of $0.31. HC Wainwright has a “Buy” rating and a $11.00 price target on the stock. The consensus estimate for Kamada’s current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Kamada’s FY2026 earnings at $0.38 EPS, FY2027 earnings at $0.45 EPS and FY2028 earnings at $0.54 EPS.

Kamada Trading Up 1.2 %

Shares of NASDAQ KMDA opened at $7.41 on Monday. The stock has a market capitalization of $425.93 million, a PE ratio of 26.46, a price-to-earnings-growth ratio of 0.97 and a beta of 0.97. The stock’s fifty day simple moving average is $7.13 and its two-hundred day simple moving average is $6.17. Kamada has a 12-month low of $4.74 and a 12-month high of $9.15.

Kamada Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be given a $0.20 dividend. The ex-dividend date is Monday, March 17th.

Institutional Trading of Kamada

Institutional investors have recently made changes to their positions in the business. Plato Investment Management Ltd acquired a new stake in shares of Kamada in the 3rd quarter worth $117,000. Public Employees Retirement System of Ohio purchased a new position in Kamada in the 3rd quarter worth $77,000. JPMorgan Chase & Co. purchased a new position in Kamada in the 4th quarter worth $67,000. Geode Capital Management LLC raised its stake in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock worth $178,000 after acquiring an additional 1,549 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in Kamada by 54.2% in the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 8,260 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.